As Revlimid sales fall, Bristol Myers turns to its next multiple myeloma pill that's a molecular glue
An experimental pill developed by Bristol Myers Squibb has shown promising efficacy in a clinical trial for advanced multiple myeloma patients who have exhausted most …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
